10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to ____________.

Commission File number 0-935

CYTOCORE, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	36-4296006
(State or Other Jurisdiction of	(I.R.S. Employer
Incorporation or Organization)	Identification No.)

4203 SW 34^th ST

Orlando, FL 32811

(Address of Principal Executive Offices)

(407) 996-9631

(Registrant’s Telephone Number, Including Area Code)

414 N Orleans, Suite 503, Chicago, Il 60654

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨ (not required) ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rue 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer ¨	Accelerated Filer ¨
Non-Accelerated Filer  ¨	Smaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

common STOCK, $0.001 par value, AT May 8, 2014: 1,907,704,296,

CYTOCORE, Inc.

Quarterly Report on Form 10-Q

Table of contents

		Page
PART I.  – FINANCIAL INFORMATION
Item 1.	Financial Statements
	a) Condensed Consolidated Balance Sheets – March 31, 2014(unaudited) and December 31, 2013	2
	b) Condensed Consolidated Statements of Operations — Three months ended March 31, 2014 and March 31, 2013 (unaudited)	3
	c) Condensed Consolidated Statements of Cash Flows — Three months ended March 31, 2014 and March 31, 2013 (unaudited)	4
	d) Notes to Unaudited Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 4.	Controls and Procedures	12
Part II. — Other Information
Item 1.	Legal Proceedings
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	12
Item 3.	Defaults upon Senior Securities	13
Item 6.	Exhibits	13
SIGNATURES		14
EXHIBIT INDEX		15
Exhibit 31.1 Section 302 Certification of Chief Executive Officer
Exhibit 31.2 Section 302 Certification of Chief Financial Officer
Exhibit 32.1 Section 906 Certification of Chief Executive Officer
Exhibit 32.2 Section 906 Certification of Chief Financial Officer

1

Part I. — Financial Information

Item 1. Financial Statements

CYTOCORE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)

	March 31,			December 31,
	2014			2013*
	(unaudited)
Assets
Current Assets:
Cash and cash equivalents	$	1		$	1
Accounts receivable		8			10
Prepaid expenses and other current assets		5			5
Total current assets		14			16
Fixed assets, net		—			5
Total assets	$	14		$	21
Liabilities and Stockholders’ Deficit
Current Liabilities:
Accounts payable		399			311
Accrued payroll costs		3,520			3,324
Advances payable to related parties		102			85
Accrued expenses		479			537
Notes payable		36			36
Total current liabilities		4,536			4,293
Commitments and Contingencies		—			—
Stockholders’ Deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 373,355 and shares issued and outstanding at March 31, 2014 and December 31, 2013 (Liquidation value of all classes of preferred stock $2,871 at March 31, 2014)		1,487			1,487
Common stock, $0.001 par value; 2,000,000,000 shares authorized; 272,080,857 and 270,530,857 shares issued and issuable and 272,061,648 and 270,511,648 shares outstanding at March 31, 2014 and December 31, 2013, respectively		272			271
Additional paid-in-capital		97,244			97,137
Treasury stock: 19,209 shares at March 31, 2014 and December 31, 2013		(327	)		(327	)
Accumulated deficit		(103,198	)		(102,840	)
Total stockholders’ deficit		(4,522	)		(4,272	)
Total liabilities and stockholders’ deficit	$	14		$	21

* Derived from audited information

See accompanying notes to these condensed consolidated financial statements.

2

CYTOCORE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited)

(Dollars in thousands, except per share amounts)

	Three Months Ended
	March 31,
	2014			2013
Net sales	$	3		$	11
Operating expenses
Cost of revenues		—			6
Research and development		54			81
Selling, general, and administrative, (net of adjustment of trade debt of $66,000 for the three months ended March 31, 2014 and net of adjustment of trade debt of $193,000 and reduction in accrued franchise tax for the three months ended March 31, 2013)		304			(35	)
Total operating expenses		358			52
Operating Income (loss)		(355	)		(41	)
Other income (expense):
Interest expense – related party		(2	)		(61	)
Interest expense		(1	)		(2	)
Total other income (expense)		(3	)		(63	)
Net loss		(358	)		(104	)
Preferred stock dividend		(36	)		(66	)
Net loss applicable to common stockholders	$	(394	)	$	(170	)
Basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)
Weighed average number of common shares outstanding		277,535,857			78,610,477

See accompanying notes to these condensed consolidated financial statements.

3

CYTOCORE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(Dollars in thousands)

	Three Months Ended
	March 31,
	2014			2013
Operating Activities:
Net loss	$	(358	)	$	(104	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		5			29
Reduction in accrual for franchise taxes		—			(173	)
Interest expense imputed on related party advances		2			61
Common stock issued for services		(21	)		20
Warrants issued for services		84			—
Gain on settlements of trade indebtedness		(66	)		(193	)
Changes in assets and liabilities:
Accounts receivable		2			109
Prepaid expenses and other current assets		—			—
Accounts payable		87			(30	)
Accrued expenses		203			195
Net cash used in operating activities		(62	)		(86	)
Investing activities:
Net cash used in investing activities		—			—
Financing activities:
Sale of common stock		45			—
Proceeds from related parties		17			55
Net cash provided by financing activities		62			55
Net increase (decrease) in cash and cash equivalents		—			(31	)
Cash and cash equivalents at the beginning of period		1			38
Cash and cash equivalents at end of period	$	1		$	7
Supplemental disclosure of cash flow information:
Cash paid for interest		—			—
Cash paid for taxes		—			—

See accompanying notes to these condensed consolidated financial statements.

4

CYTOCORE, INC.

Notes to Consolidated Financial Statements

(Tabular data in thousands, except per share amounts)

(Unaudited)

Note 1. Organization

CytoCore, Inc. (“CCI”, “CytoCore” or the “Company”) was incorporated in Delaware in December 1998.

Except where the context otherwise requires, “CCI,” “CytoCore”, the “Company,” “we” and “our” refers to CytoCore, Inc. and our dormant subsidiaries and predecessors.

Currently, CCI has one product for sale – its SoftPap collector. CCI is developing, and plans to sell an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions®. CytoCore Solutions products are intended to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), treatment and patient monitoring within vertical markets related to specific cancers. Current CytoCore Solutions products are focused upon cervical cancer. CCI plans that this focus will later be expanded to include other gynecological cancers as well as bladder, lung, and breast cancers, among others. Within each of these markets CCI anticipates that the CytoCore Solutions products will be sold as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations

Note 2. Basis of Presentation

The consolidated financial statements for the periods ended March 31, 2014 and 2013 included herein are unaudited. Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2014 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the Securities and Exchange Commission (“SEC”) on April 14, 2014.

The Company does not have any comprehensive income or loss.

Note 3. Fixed Assets

Fixed assets consist of the following:

	March 31,			December 31,
	2014			2013
Furniture and fixtures	$	40		$	40
Laboratory equipment		508			508
Computer and communications equipment		261			261
Design and tooling		1,204			1,204
		2,013			2,013
Less accumulated depreciation and amortization		(2,013	)		(2,008	)
Total	$	—		$	5

5

For the quarters ended March 31, 2014 and 2013, depreciation expense was approximately $5,000 and $29,000, respectively. The Company did not allocate any of the depreciation expense of the machinery and equipment or the design and tooling into inventory since the Company has suspended manufacturing. This depreciation was included as a selling, general and administrative expense as excess idle time.

Note 4. Accrued Expenses

Accrued expenses include the following:

	March 31,		December 31,
	2014		2013
Accrued interest	$	31	$	30
Accrued franchise and other taxes		341		328
Accrued compensation		50		40
Other accrued expenses		57		139
Total	$	479	$	537

Note 5. Notes Payable and Advances-related parties

Notes payable to unrelated parties consist of:

	March 31,		December 31,
	2014		2013
Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate 9% per annum, due December 20, 2001.		15		15
Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; due December 31, 2003; interest rate 8% per annum payable after December 31, 2003		21		21
	$	36	$	36

The Company has failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above. Such notes require the holder to notify the Company in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. The Company has not received any written declarations of default from holders of its remaining outstanding notes payable.

During the three months ended March 31, 2014, the Company was advanced $17,000 from a related party. These advances are non-interest bearing and are due on demand. However, using an 8% annual interest rate, the Company has recorded a non-cash interest expense totaling approximately $2,000 on the outstanding balance for the quarter.

Note 6. Stockholders’ Equity (Deficit)

Loss per share

A reconciliation of the numerator and the denominator used in the calculation of loss per share is as follows:

	March 31,			March 31,
	2014			2013
Basic and Diluted:
Net loss applicable to common stockholder (in thousands)	$	(394	)	$	(170	)
Weighted average common shares outstanding		277,535,857			78,610,477
Net loss per common share	$	(0.00	)	$	(0.00	)

6

Warrants to purchase 2,839,000 and 705,667 common shares and preferred stock convertible into 484,566 and 471,105 common shares were not included in the computation of diluted loss per share applicable to common stockholders as they are anti-dilutive as a result of net losses for the periods ended March 31, 2014 and March 31, 2013, respectively.

Preferred Stock

A summary of the Company’s preferred stock is as follows:

	March 31,		December 31,
	2014		2013
	Shares Issued &		Shares Issued &
Offering	Outstanding		Outstanding
Series A convertible		47,250		47,250
Series B convertible, 10% cumulative dividend		93,750		93,750
Series C convertible, 10% cumulative dividend		38,333		38,333
Series D convertible, 10% cumulative dividend		175,000		175,000
Series E convertible, 10% cumulative dividend		19,022		19,022
Total Preferred Stock		373,355		373,355

As of March 31, 2014 and 2013, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation.

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:	$4.50 per share, $212,625
Conversion Price:	$103.034 per share
Conversion Rate:	0.04367—Liquidation Value divided by Conversion Price ($4.50/$103.034)
Voting Rights:	None
Dividends:	None
Conversion Period:	Any time

Series B Convertible Preferred Stock

Liquidation Value:	$4.00 per share, $375,000
Conversion Price:	$10.00 per share
Conversion Rate:	0.40—Liquidation Value divided by Conversion Price ($4.00/$10.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2001
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $491,000

Series C Convertible Preferred Stock

Liquidation Value:	$3.00 per share, $115,000
Conversion Price:	$6.00 per share
Conversion Rate:	0.50—Liquidation Value divided by Conversion Price ($3.00/$6.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $143,000

Series D Convertible Preferred Stock

Liquidation Value:	$10.00 per share, $525,000
Conversion Price:	$10.00 per share
Conversion Rate:	1.00—Liquidation Value divided by Conversion Price ($10.00/$10.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing April 30, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $643,000

7

Series E Convertible Preferred Stock

Liquidation Value:	$22.00 per share, $418,488
Conversion Price:	$8.00 per share
Conversion Rate:	2.75—Liquidation Value divided by Conversion Price ($22.00/$8.00)
Voting Rights:	Equal in all respects to holders of common shares
Dividends:	10%—Quarterly—Commencing May 31, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $522,000

Sale of Common Stock

During the quarter ended March 31, 2014, the Company sold 1,250,000 shares of restricted, unregistered common stock to an affiliate of Dr. John Abeles, a director of the Company for $25,000 or $0.02 per share. In addition, the Company will issue warrants to purchase 2,800,000 shares of common stock of the Company to Dr. Abeles for services rendered to the Company. The warrants have a term of ten years and are exercisable at $0.04 per share. The warrants are callable by the Company if the closing bid price of the Company’s common stock exceeds 100% of the exercise price for a period of ninety trading days. The warrants became issuable upon the change of control of the Company and may be exercised at any time. The Company valued the warrants at $84,000 and expensed them to selling, general and administrative expense. The Company used the Black Scholes Merton pricing model with the significant assumptions of $0.03 per share fair value of the underlying common stock, term of 5 years, risk free rate of 1%.

Also, during the quarter ended March 31, 2014, the Company sold 1,000,000 shares of restricted, unregistered common stock to a qualified investor for $20,000 or $0.02 per share.

Reversal of the Issuance of Common Stock as payment for Services

During the quarter ended March 31, 2014, the Company reversed $21,000 of consulting compensation expense from a consulting agreement issued several years prior. The consultant never completed any of the tasks required under the contract and therefore did not meet the requirements to vest any of the 700,000 shares granted, but never issued, under the contract. The $21,000 was a reduction in selling, general & administrative expense.

Note 7. Commitments and Contingencies

Legal Proceedings

There are no pending legal proceedings against the Company. To the Company’s knowledge, there have been no cases initiated by or against the Company, nor any cases resolved, since the date of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 was filed with the SEC.

The Company has been a party to a number of other proceedings, informal demands, or debt for services brought by former unsecured creditors to collect past due amounts for services. The Company is attempting to settle these demands and unfilled claims. The Company does not consider any of these claims to be material.

During the quarter ended March 31, 2014, the Company recorded a settlement totaling $66,000 of trade debt. The settlement was recorded as a reduction of selling, general and administration expense.

Contingencies

The Company has not filed its franchise returns for 2013, 2012, 2011, 2010 and 2009 or paid its franchise tax for those years. The Company believes that it has made adequate provision for the liability including penalties and interest.

8

Note 8. Subsequent Events

On April 3, 2014, the Company acquired 100% of the issued and outstanding capital stock of Medite Enterprises, Inc. and its wholly owned subsidiaries (“Medite”)and issued in consideration 1,468,750,000 of the Company’s common stock to the shareholders of Medite. Also, the Company issued 69,723,439 shares of common stock as payment for approximately $1.6 million in accrued wages owed by the Company.

Concurrent with the closing of the acquisition of Medite, the Company had an initial closing of the a private placement of the Company’s common stock. Pursuant to the Securities Purchase Agreement the Company issued 95,587,500 shares of common stock to accredited investors at an aggregate gross purchase price of $1,529,400. In conjunction with the issuance of the common stock, the Company paid cash commissions of $46,298, or 7%, to a placement agent.

Subsequent to the closing, the Company raised additional gross proceeds of $100,000 under the Private Placement.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Caution Regarding Forward-Looking Statements

This report contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our ability to raise capital; our ability to retain key employees; our ability to engage third party distributors to sell our products; economic conditions; technological advances in the medical field; demand and market acceptance risks for new and existing products, technologies, and healthcare services; the impact of competitive products and pricing; U.S. and international regulatory, trade, and tax policies; product development risks, including technological difficulties; ability to enforce patents; and foreseeable and unforeseeable foreign regulatory and commercialization factors, our ability to develop new products and respond to technological changes in the markets in which we compete, our ability to obtain government approvals of our products, our ability to market our products, changes in third-party reimbursement procedures, and such other factors that may be identified from time to time in our Securities and Exchange Commission ("SEC") filings and other public announcements including those set forth under the caption “Risk Factors” in Part 1, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Except as required by law, we assume no duty to update or revise our forward-looking statements.

Overview of CytoCore, Inc.

Cytocore, Inc. (the “Company,” “we” or “us”) is developing an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions^®. Currently, we have one of our own products for sale – our SoftPap collector. We are developing, and plan to sell an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions®. Our products are intended to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), and patient treatment and monitoring within vertical markets related to specific cancers. Current CytoCore Solutions products are focused upon cervical cancer. We plan to expand our focus to include other gynecological cancers as well as bladder, lung and breast cancers, among others. Within each of these markets, we anticipate that the CytoCore Solutions products will be sold as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations.

9

The science of medical diagnostics has advanced significantly during the past decade. Much of this advance has come as a result of new knowledge of the human genome and related proteins, which form the foundation of cell biology and the functioning of the human body. Our goal is to utilize this research as a base to develop screening and diagnostic testing products for cancer and cancer-related diseases. We believe that the success of these products will improve patient care through more accurate test performance, wider product availability and more cost-effective service delivery. We have developed the SoftPAP®, a sample collection device approved by the U.S. Food and Drug Administration, and are licensed to sell the PadKitÔ collection device and GluCyteÔ cell preservative. We are focusing on the development and testing of cocktail assay markers and stains for use with the Company’s Automated Image Proteomic System (AIPSÔ) to screen for various cancers.

On April 3, 2014, we acquired 100% of the issued and outstanding capital stock of Medite. Medite specializes in the development, manufacture and distribution of medical laboratory automation equipment and supplies for pathology, histology and cytology. Medite’s focus is on the development of medical devices for the detection, risk assessment and diagnosis of cancer and related diseases.

Our strategy is to develop products through internal development processes, strategic partnerships, licenses and acquisitions. This strategy has required and will continue to require additional capital. As a result, we will incur substantial operating losses until we are able to successfully market our products.

Outlook

We have incurred significant losses since inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement our business plan and develop, manufacture and market our products. During the year ended December 31, 2013, we raised approximately $460,000 through the sale of common stock and advances from related parties. During the three months ended March 31, 2014, we raised approximately $62,000 through the sale of common stock and advances from related parties.

On April 3, 2014, in conjunction with the acquisition of Medite we closed on a private placement and received net proceeds totaling $1,529,400. We may require additional capital to complete our business plan. No assurances can be given about our ability to obtain capital.

Results of Operations

The following discussion and analysis should be read in conjunction with our unaudited consolidated financial statements presented in Part I, Item 1 of this Quarterly Report and the notes thereto, and our audited consolidated financial statements and notes thereto, as well as our Management’s Discussion and Analysis, contained in our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on April 14, 2014.

Three Months Ended March 31, 2014 as compared to Three Months Ended March 31, 2013

Revenue

Revenues for the three months ended March 31, 2014 decreased $8,000, or 73%, to $3,000 from $11,000 for the three months ended March 31, 2013. There were no sales of the collection system relating to the detection of breast cancer. Licensing revenue decreased approximately $1,000 to $3,000 for the quarter ended March 31, 2014.

Costs and Expenses

Cost of Revenues

There was no cost of revenues for the quarter ended March 31, 2014, as a result of zero of the collection system relating to the detection of breast cancer. Cost of revenues for the quarter ended March 31, 2013 was $6,000.

10

Research and Development

For the three months ended March 31, 2014, our research and development (“R&D”) expenses were $54,000, a $27,000, or 33%, decrease from $81,000 for the corresponding period in 2013. Of this $27,000 decrease, $15,000 related to a decrease in consultants costs, $4,000 related to a decrease in payroll costs and $8,000 related to a decrease in other project expenses,

R&D expenses consisted primarily of costs related to specific development programs with scientists and researchers and expenses incurred by engineers and researchers at our Chicago facility.

Selling, General and Administrative

For the three months ended March 31, 2014, selling, general and administrative expenses (“SG&A”) were $370,000 before an adjustment of trade debt totaling $66,000. Expenses for the quarter ended March 31, 2013 were $304,000 before an adjustment of trade debt totaling $193,000 and a reduction in the franchise taxes of $146,000, for a net gain of $35,000. The SG&A expenses represent a $66,000, or 22%, increase in the quarter ended March 31, 2014. Of this $66,000 increase, directors fees increase $84,000, professional fees increased $30,000, and payroll expense increased $16,000. These increases were partially offset by a decrease in depreciation expense of $24,000, a decrease in marketing costs of $12,000, a decrease in rent expense of $25,000, a decrease in payments made to consultants of $21,000, a decrease in insurance expense of $2,000 and a decrease in other costs of $6,000.

Other Income (Expense)

Interest expense decreased $60,000 to $3,000 for the three month period ended March 31, 2014 from $63,000 for the three month period quarter ended March 31, 2013. Of this decrease, $59,000 relates to the non-cash charge for related party advances that were converted to equity in the second quarter of 2013.

Net Loss

The net loss from operations for the three-month period ended March 31, 2014 was $358,000, as compared to $104,000 for the corresponding period in 2013, an increase of $254,000, or 244%. Of this increase, $359,000 resulted from the increase in SG&A expenses and a decrease in revenues partially offset by a decrease in R&D and interest expense.

The net loss applicable to common stockholders, which reflects the unpaid and undeclared preferred stock dividends from the period, increased to $394,000 for the quarter ended March 31, 2014 from $170,000 for the quarter ended March 31, 2013, an increase of $224,000, or 132%. The net loss per common share for each of the three month periods ended March 31, 2014 and March 31, 2013 was $0.00 per share on 277,535,857 and 78,610,477 weighted average common shares outstanding, respectively.

Liquidity and Capital Resources

To date, our capital resources and liquidity needs have been met from advances from related parties, and sales of our debt and equity securities to individual and institutional investors.

Research and development, clinical trials and other studies of the components of our CytoCore Solutions System, conversions from designs and prototypes into products and product manufacturing, sales and marketing efforts, medical consultants and advisors, and research, administrative and executive personnel are and will continue to be the principal basis for our cash requirements. We have obtained operating funds for the business since inception through private offerings of debt and equity securities to U.S. accredited and foreign investors. We will be required to make additional offerings in the future to support our operations until we are able to generate sufficient income from the sale of our products. We used $62,000 for operating activities during the three months ended March 31, 2014 compared to $86,000 during the three months ended March 31, 2013. During the quarter ending March 31, 2014, approximately $54,000 was incurred for R&D and approximately $305,000 was incurred for SG&A functions.

We did not engage any investing activity during the quarter ended March 31, 2014. At this time, we have no other material commitments for capital expenditures during the remainder of the 2014 fiscal year.

11

We were able to raise proceeds of $62,000 through the sale of our common stock and advances from related parties during the three months ended March 31, 2014. The proceeds were used to develop our products and satisfy certain present and past obligations. At March 31, 2014, we had $2,000 of cash on hand. We believe that our current cash resources after the closing of our Private Placement on April 3, 2014, which raised gross proceeds of $1.529 million, will be sufficient to fund operations for the next twelve months. We continue to meet with qualified investors and although no assurance can be given, we believe will be able to raise capital to fund operations in the immediate future until we can be self-sufficient through operations.

Our operations have been, and will continue to be, dependent upon management’s ability to raise operating capital through the issuance and sale of debt and equity securities and advances from related parties. We have incurred significant operating losses since inception of the business. We expect that significant on-going operating expenditures will be necessary to successfully implement our business plan and develop, manufacture and market our products.

Off-Balance Sheet Arrangements

As of March 31, 2014, we did not have any relationships with unconsolidated entities or financial partners, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, the “Exchange Act”) as of the end of the period covered by this report. Based on that evaluation, our chief executive and chief financial officers have concluded that our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II. Other Information

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended March 31, 2014, the Company sold 1,250,000 shares of restricted, unregistered common stock to an affiliate of Dr. John Abeles, a director of the Company for $25,000 or $0.02 per share. In addition, for services rendered, the Company will issue 2,800,000 warrants to Dr. Abeles to purchase the common stock of the Company. The warrants have at term of ten years and are exercisable at $0.04 per share. The warrants are callable by the Company if the closing bid price of the Company’s common stock exceeds 100% of the exercise price for a period of ninety trading days. The warrants became issuable upon the change of control of the Company and may be exercised at any time.

Also, during the quarter ended March 31, 2014, the Company sold 1,000,000 shares of restricted, unregistered common stock to a qualified investor for $20,000 or $0.02 per share.

We issued the foregoing securities in reliance on the safe harbor and exemptions from registration provided by Section 4(2) of the Securities Act of 1933, as amended, for sales to a limited number of accredited investors, employees, service providers, or creditors with whom we had prior relationships, without engaging in any general solicitation, and without payment of underwriter discounts or commissions to any person.

12

Item 3.Defaults upon Senior Securities

As of March 31, 2014, we failed to make the required principal and interest payments, constituting events of default, on the $21,000 Ventana Medical Systems, Inc. promissory note. The note requires the holder to notify us in writing of a declaration of default at which time a cure period, as specified in the note, would commence. There is no guarantee that we will be able to cure any event of default if, or when, the holder provides the required written notice.

Item 6. Exhibits

Exhibit
Number	Description
31.1	Section 302 certification by the principal executive officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
31.2	Section 302 certification by the chief financial officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1	Section 906 certification by the principal executive pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
32.2	Section 906 certification by the chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS	XBRL Instance
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation
101.DEF	XBRL Taxonomy Extension Definition
101.LAB	XBRL Taxonomy Extension Labels
101.PRE	XBRL Taxonomy Extension Presentation

13

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoCore, Inc.
Date:  May 15, 2014	/s/ Michaela Ott
	Michaela Ott
	Chief Executive Officer
Date: May 15, 2014	s/ Robert F. McCullough, Jr.
	Robert F. McCullough, Jr.
	Chief Financial Officer

14

EXHIBIT INDEX

Exhibit
Number	Description
31.1	Section 302 certification by the principal executive officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
31.2	Section 302 certification by the chief financial officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1	Section 906 certification by the principal executive officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
32.2	Section 906 certification by the chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS	XBRL Instance
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation
101.DEF	XBRL Taxonomy Extension Definition
101.LAB	XBRL Taxonomy Extension Labels
101.PRE	XBRL Taxonomy Extension Presentation

15

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Michaela Ott, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of CytoCore, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Michaela Ott

Michaela Ott

Chief Executive Officer

Dated:  May 15, 2014

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Robert F. McCullough Jr., certify that:

(1) I have reviewed this quarterly report on Form 10-Q of CytoCore, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Robert F. McCullough Jr.

Robert F. McCullough Jr.

Chief Financial Officer

Dated:  May 15, 2014

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cytocore, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2014, filed with the Securities and Exchange Commission (the “Report”), I, Michaela Ott, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition as of the dates presented and the results of operations of the Company for the periods presented.

/s/ Michaela Ott

Michaela Ott

Chief Executive Officer

Dated:  May 15, 2014

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cytocore, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2014, filed with the Securities and Exchange Commission (the “Report”), I, Robert McCullough, Jr., Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition as of the dates presented and the results of operations of the Company for the periods presented.

/s/ Robert F. McCullough, Jr.

Robert F. McCullough, Jr.

Chief Financial Officer

Dated:  May 15, 2014

XML

Stockholders' Equity (Deficit) (Reconciliation of Numerator and Denominator Used in Calculation of Loss Per Share) (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Basic and Diluted:
Net loss applicable to common stockholder (in thousands)	$ (394)	$ (170)
Weighted average common shares outstanding	277,535,857	78,610,477
Net loss per common share	$ 0.00	$ 0.00

XML

Fixed Assets

3 Months Ended

Mar. 31, 2014

Property, Plant and Equipment [Abstract]

Fixed Assets

Note 3. Fixed Assets

Fixed assets consist of the following:

	March 31,		December 31,
	2014		2013
Furniture and fixtures	$	40	$	40
Laboratory equipment		508		508
Computer and communications equipment		261		261
Design and tooling		1,204		1,204
		2,013		2,013
Less accumulated depreciation and amortization		(2,013)		(2,008)
Total	$	—	$	5

For the quarters ended March 31, 2014 and 2013, depreciation expense was approximately $5,000 and $29,000, respectively. The Company did not allocate any of the depreciation expense of the machinery and equipment or the design and tooling into inventory since the Company has suspended manufacturing. This depreciation was included as a selling, general and administrative expense as excess idle time.

XML

Stockholders' Equity (Deficit) (Summary of Preferred Stock Terms) (Parenthetical) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 4.50
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 4.00
Preferred stock, frequency of dividend payment	10%—Quarterly—Commencing March 31, 2001
Preferred stock, dividend date of commencement	Mar. 31, 2001
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 3.00
Preferred stock, frequency of dividend payment	10%—Quarterly—Commencing March 31, 2002
Preferred stock, dividend date of commencement	Mar. 31, 2002
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 10.00
Preferred stock, frequency of dividend payment	10%—Quarterly—Commencing April 30, 2002
Preferred stock, dividend date of commencement	Apr. 30, 2002
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 22.00
Preferred stock, frequency of dividend payment	10%—Quarterly—Commencing May 31, 2002
Preferred stock, dividend date of commencement	May 31, 2002

XML

Stockholders' Equity (Deficit) (Summary of Preferred Stock Terms) (Detail) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	Mar. 15, 2014	Mar. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Preferred stock, Liquidation value		$ 2,871,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, Liquidation value		212,625
Preferred stock, conversion Price		$ 103.034
Preferred stock, conversion Rate		0.04367%
Preferred stock, voting Rights		None
Preferred stock, dividends		0.00%
Preferred stock, conversion Period		Any time
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, Liquidation value		375,000
Preferred stock, conversion Price		$ 10.00
Preferred stock, conversion Rate		0.40%
Preferred stock, voting Rights		None
Preferred stock, dividends		10.00%	10.00%
Preferred stock, conversion Period		Any time
Preferred stock, cumulative and undeclared dividends in arrears		491,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, Liquidation value		115,000
Preferred stock, conversion Price		$ 6.00
Preferred stock, conversion Rate		0.50%
Preferred stock, voting Rights		None
Preferred stock, dividends		10.00%	10.00%
Preferred stock, conversion Period		Any time
Preferred stock, cumulative and undeclared dividends in arrears		143,000
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, Liquidation value		525,000
Preferred stock, conversion Price		$ 10.00
Preferred stock, conversion Rate		1.00%
Preferred stock, voting Rights		None
Preferred stock, dividends	10.00%	10.00%	10.00%
Preferred stock, conversion Period		Any time
Preferred stock, cumulative and undeclared dividends in arrears		643,000
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, Liquidation value		418,488
Preferred stock, conversion Price		$ 8.00
Preferred stock, conversion Rate		2.75%
Preferred stock, voting Rights		Equal in all respects to holders of common shares
Preferred stock, dividends		10.00%	10.00%
Preferred stock, conversion Period		Any time
Preferred stock, cumulative and undeclared dividends in arrears		$ 522,000

XML

Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stockholders Equity Note [Line Items]
Proceeds from Issuance of Common Stock	$ 45,000	$ 0
Warrant Term	10 years
Resulting weighted average grant date fair value	$ 0.03
Expected term (years)	5 years
Risk-free interest rate	1.00%
Warrant [Member]
Stockholders Equity Note [Line Items]
Fair Value Of Warrants	84,000
Consultant [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Shares, Issued for Services	700,000
Issuance of Stock and Warrants for Services or Claims	21,000
Selling General And Administrative Expense Decrease Amount	21,000
Restricted Common Stock [Member] | Qualified Investor [Member]
Stockholders Equity Note [Line Items]
Share Price	$ 0.02
Stock Issued During Period, Shares, New Issues	1,000,000
Proceeds from Issuance of Common Stock	20,000
Warrants and Stock Options [Member]
Stockholders Equity Note [Line Items]
Anti-dilutive securities not included in the computation of diluted loss per share	2,839,000	705,667
Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Anti-dilutive securities not included in the computation of diluted loss per share	484,566	471,105
Affiliated Entity [Member]
Stockholders Equity Note [Line Items]
Class Of Warrants Or Rights Issuable	2,800,000
Class Of Warrant Or Right Expiration Term	10 years
Class Of Warrants Or Rights Callable Description	The warrants are callable by the Company if the closing bid price of the Companys common stock exceeds 100% of the exercise price for a period of ninety trading days
Affiliated Entity [Member] | First Five Years [Member]
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.04
Affiliated Entity [Member] | Restricted Common Stock [Member]
Stockholders Equity Note [Line Items]
Share Price	$ 0.02
Stock Issued During Period, Shares, New Issues	1,250,000
Proceeds from Issuance of Common Stock	$ 25,000

XML

Commitments and Contingencies - Additional Information (Detail) (Selling, General and Administrative Expenses [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Selling, General and Administrative Expenses [Member]
Commitments and Contingencies Disclosure [Line Items]
Settlement of trade debt	$ 66,000

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

Note 2. Basis of Presentation

The consolidated financial statements for the periods ended March 31, 2014 and 2013 included herein are unaudited. Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2014 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the Securities and Exchange Commission (“SEC”) on April 14, 2014.

The Company does not have any comprehensive income or loss.

XML

Subsequent Events Additional Information (Detail) (Subsequent Event [Member], USD $)	0 Months Ended	3 Months Ended
	Apr. 03, 2014	Mar. 31, 2014
Subsequent Event [Line Items]
Proceeds from Issuance of Private Placement		$ 100,000
Commissions Paid To Placement Agent	46,298
Payments to Acquire Businesses, Gross	1,529,400
Percentage Of Commission Paid To Placement Agent	7.00%
Accredited Investors [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Acquisitions	95,587,500
Medite Enterprises, Inc.,[Member]
Subsequent Event [Line Items]
Accrued Salaries	$ 1,600,000
Medite Enterprises, Inc.,[Member] | Amended Stock Purchase Agreement [Member]
Subsequent Event [Line Items]
Equity Method Investment, Ownership Percentage	100.00%
Stock Issued During Period, Shares, Acquisitions	1,468,750,000
Stock Issued During Period, Shares, Share-based Compensation, Gross	69,723,439

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$ 1	$ 1	[1]
Accounts receivable	8	10	[1]
Prepaid expenses and other current assets	5	5	[1]
Total current assets	14	16	[1]
Fixed assets, net	0	5	[1]
Total assets	14	21	[1]
Current Liabilities:
Accounts payable	399	311	[1]
Accrued payroll costs	3,520	3,324	[1]
Advances payable to related parties	102	85	[1]
Accrued expenses	479	537	[1]
Notes payable	36	36	[1]
Total current liabilities	4,536	4,293	[1]
Commitments and Contingencies			[1]
Stockholders' Deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 373,355 and shares issued and outstanding at March 31, 2014 and December 31, 2013 (Liquidation value of all classes of preferred stock $2,871 at March 31, 2014)	1,487	1,487	[1]
Common stock, $0.001 par value; 2,000,000,000 shares authorized; 272,080,857 and 270,530,857 shares issued and issuable and 272,061,648 and 270,511,648 shares outstanding at March 31, 2014 and December 31, 2013, respectively	272	271	[1]
Additional paid-in-capital	97,244	97,137	[1]
Treasury stock: 19,209 shares at March 31, 2014 and December 31, 2013	(327)	(327)	[1]
Accumulated deficit	(103,198)	(102,840)	[1]
Total stockholders' deficit	(4,522)	(4,272)	[1]
Total liabilities and stockholders' deficit	$ 14	$ 21	[1]

[1] Derived from audited information

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Operating Activities:
Net loss	$ (358)		$ (104)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	5		29
Reduction in accrual for franchise taxes	0		(173)
Interest expense imputed on related party advances	2		61
Common stock issued for services	(21)		20
Warrants issued for services	84		0
Gain on settlements of trade indebtedness	(66)		(193)
Changes in assets and liabilities:
Accounts receivable	2		109
Prepaid expenses and other current assets	0		0
Accounts payable	87		(30)
Accrued expenses	203		195
Net cash used in operating activities	(62)		(86)
Investing activities:
Net cash used in investing activities	0		0
Financing activities:
Sale of common stock	45		0
Proceeds from related parties	17		55
Net cash provided by financing activities	62		55
Net increase (decrease) in cash and cash equivalents	0		(31)
Cash and cash equivalents at the beginning of period	1	[1]	38
Cash and cash equivalents at end of period	1		7
Supplemental disclosure of cash flow information:
Cash paid for interest	0		0
Cash paid for taxes	$ 0		$ 0

[1] Derived from audited information

XML

Notes Payable and Advances-related parties (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Notes payable	$ 36	$ 36	[1]
Robert Shaw [Member]
Debt Instrument [Line Items]
Notes payable	15	15
Ventana Medical Systems, Inc [Member]
Debt Instrument [Line Items]
Notes payable	$ 21	$ 21

[1] Derived from audited information

XML

Notes Payable and Advances-related parties - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Debt Instrument [Line Items]
Advance from related party	$ 17	$ 55
Annual interest rate	8.00%
Non-cash interest expense	$ 2	$ 61

XML

Organization

3 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Note 1. Organization

CytoCore, Inc. (“CCI”, “CytoCore” or the “Company”) was incorporated in Delaware in December 1998.

Except where the context otherwise requires, “CCI,” “CytoCore”, the “Company,” “we” and “our” refers to CytoCore, Inc. and our dormant subsidiaries and predecessors.

Currently, CCI has one product for sale – its SoftPap collector. CCI is developing, and plans to sell an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions®. CytoCore Solutions products are intended to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), treatment and patient monitoring within vertical markets related to specific cancers. Current CytoCore Solutions products are focused upon cervical cancer. CCI plans that this focus will later be expanded to include other gynecological cancers as well as bladder, lung, and breast cancers, among others. Within each of these markets CCI anticipates that the CytoCore Solutions products will be sold as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred stock, shares issued	373,355	373,355
Preferred stock, shares outstanding	373,355	373,355
Preferred stock, Liquidation value	$ 2,871
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common Stock, Shares, Issued	272,080,857	270,530,857
Common Stock, Shares, Outstanding	272,061,648	270,511,648
Treasury stock, shares	19,209	19,209

XML

Notes Payable and Advances-related parties (Tables)

3 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Notes Payable to Unrelated Parties

Notes payable to unrelated parties consist of:

	March 31,		December 31,
	2014		2013
Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate 9% per annum, due December 20, 2001.		15		15
Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; due December 31, 2003; interest rate 8% per annum payable after December 31, 2003		21		21
	$	36	$	36

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	May 08, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Trading Symbol	CYOE
Entity Registrant Name	CytoCore Inc
Entity Central Index Key	0000075439
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		1,907,704,296

XML

Stockholders' Equity (Deficit) (Tables)

3 Months Ended

Mar. 31, 2014

Stockholders' Equity (Deficit) [Abstract]

Schedule of Calculation of Numerator and Denominator in Earnings Per Share

A reconciliation of the numerator and the denominator used in the calculation of loss per share is as follows:

	March 31,		March 31,
	2014		2013
Basic and Diluted:
Net loss applicable to common stockholder (in thousands)	$	(394)	$	(170)
Weighted average common shares outstanding		277,535,857		78,610,477
Net loss per common share	$	(0.00)	$	(0.00)

Summary of Company's Preferred Stock

A summary of the Company’s preferred stock is as follows:

	March 31,		December 31,
	2014		2013
	Shares Issued &		Shares Issued &
Offering	Outstanding		Outstanding
Series A convertible		47,250		47,250
Series B convertible, 10% cumulative dividend		93,750		93,750
Series C convertible, 10% cumulative dividend		38,333		38,333
Series D convertible, 10% cumulative dividend		175,000		175,000
Series E convertible, 10% cumulative dividend		19,022		19,022
Total Preferred Stock		373,355		373,355

Summary of Preferred Stock Terms

As of March 31, 2014 and 2013, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation.

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:	$4.50 per share, $212,625
Conversion Price:	$103.034 per share
Conversion Rate:	0.04367—Liquidation Value divided by Conversion Price ($4.50/$103.034)
Voting Rights:	None
Dividends:	None
Conversion Period:	Any time

Series B Convertible Preferred Stock

Liquidation Value:	$4.00 per share, $375,000
Conversion Price:	$10.00 per share
Conversion Rate:	0.40—Liquidation Value divided by Conversion Price ($4.00/$10.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2001
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $491,000

Series C Convertible Preferred Stock

Liquidation Value:	$3.00 per share, $115,000
Conversion Price:	$6.00 per share
Conversion Rate:	0.50—Liquidation Value divided by Conversion Price ($3.00/$6.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $143,000

Series D Convertible Preferred Stock

Liquidation Value:	$10.00 per share, $525,000
Conversion Price:	$10.00 per share
Conversion Rate:	1.00—Liquidation Value divided by Conversion Price ($10.00/$10.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing April 30, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $643,000

Series E Convertible Preferred Stock

Liquidation Value:	$22.00 per share, $418,488
Conversion Price:	$8.00 per share
Conversion Rate:	2.75—Liquidation Value divided by Conversion Price ($22.00/$8.00)
Voting Rights:	Equal in all respects to holders of common shares
Dividends:	10%—Quarterly—Commencing May 31, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $522,000

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net sales	$ 3	$ 11
Operating expenses
Cost of revenues	0	6
Research and development	54	81
Selling, general, and administrative, (net of adjustment of trade debt of $66,000 for the three months ended March 31, 2014 and net of adjustment of trade debt of $193,000 and reduction in accrued franchise tax for the three months ended March 31, 2013) .	304	(35)
Total operating expenses	358	52
Operating Income (loss)	(355)	(41)
Other income (expense):
Interest expense - related party	(2)	(61)
Interest expense	(1)	(2)
Total other income (expense)	(3)	(63)
Net loss	(358)	(104)
Preferred stock dividend	(36)	(66)
Net loss applicable to common stockholders	$ (394)	$ (170)
Basic and diluted net loss per common share	$ 0.00	$ 0.00
Weighed average number of common shares outstanding	277,535,857	78,610,477

XML

Stockholders' Equity (Deficit)

3 Months Ended

Mar. 31, 2014

Stockholders' Equity (Deficit) [Abstract]

Stockholders' Equity

Note 6. Stockholders’ Equity (Deficit)

 

Loss per share

A reconciliation of the numerator and the denominator used in the calculation of loss per share is as follows:

	March 31,		March 31,
	2014		2013
Basic and Diluted:
Net loss applicable to common stockholder (in thousands)	$	(394)	$	(170)
Weighted average common shares outstanding		277,535,857		78,610,477
Net loss per common share	$	(0.00)	$	(0.00)

Warrants to purchase 2,839,000 and 705,667 common shares and preferred stock convertible into 484,566 and 471,105 common shares were not included in the computation of diluted loss per share applicable to common stockholders as they are anti-dilutive as a result of net losses for the periods ended March 31, 2014 and March 31, 2013, respectively.

Preferred Stock

A summary of the Company’s preferred stock is as follows:

	March 31,		December 31,
	2014		2013
	Shares Issued &		Shares Issued &
Offering	Outstanding		Outstanding
Series A convertible		47,250		47,250
Series B convertible, 10% cumulative dividend		93,750		93,750
Series C convertible, 10% cumulative dividend		38,333		38,333
Series D convertible, 10% cumulative dividend		175,000		175,000
Series E convertible, 10% cumulative dividend		19,022		19,022
Total Preferred Stock		373,355		373,355

As of March 31, 2014 and 2013, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation.

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:	$4.50 per share, $212,625
Conversion Price:	$103.034 per share
Conversion Rate:	0.04367—Liquidation Value divided by Conversion Price ($4.50/$103.034)
Voting Rights:	None
Dividends:	None
Conversion Period:	Any time

Series B Convertible Preferred Stock

Liquidation Value:	$4.00 per share, $375,000
Conversion Price:	$10.00 per share
Conversion Rate:	0.40—Liquidation Value divided by Conversion Price ($4.00/$10.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2001
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $491,000

Series C Convertible Preferred Stock

Liquidation Value:	$3.00 per share, $115,000
Conversion Price:	$6.00 per share
Conversion Rate:	0.50—Liquidation Value divided by Conversion Price ($3.00/$6.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $143,000

Series D Convertible Preferred Stock

Liquidation Value:	$10.00 per share, $525,000
Conversion Price:	$10.00 per share
Conversion Rate:	1.00—Liquidation Value divided by Conversion Price ($10.00/$10.00)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing April 30, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $643,000

Series E Convertible Preferred Stock

Liquidation Value:	$22.00 per share, $418,488
Conversion Price:	$8.00 per share
Conversion Rate:	2.75—Liquidation Value divided by Conversion Price ($22.00/$8.00)
Voting Rights:	Equal in all respects to holders of common shares
Dividends:	10%—Quarterly—Commencing May 31, 2002
Conversion Period:	Any time

Cumulative and undeclared dividends in arrears at March 31, 2014 were $522,000

Sale of Common Stock

During the quarter ended March 31, 2014, the Company sold 1,250,000 shares of restricted, unregistered common stock to an affiliate of Dr. John Abeles, a director of the Company for $25,000 or $0.02 per share. In addition, the Company will issue warrants to purchase  2,800,000 shares of common stock of the Company to Dr. Abeles for services rendered to the Company. The warrants have a term of ten years and are exercisable at $0.04 per share. The warrants are callable by the Company if the closing bid price of the Company’s common stock exceeds 100% of the exercise price for a period of ninety trading days. The warrants became issuable upon the change of control of the Company and may be exercised at any time. The Company valued the warrants at $84,000 and expensed them to selling, general and administrative expense. The Company used the Black Scholes Merton pricing model with the significant assumptions of $0.03 per share fair value of the underlying common stock, term of 5 years, risk free rate of 1%.

Also, during the quarter ended March 31, 2014, the Company sold 1,000,000 shares of restricted, unregistered common stock to a qualified investor for $20,000 or $0.02 per share.

Reversal of the Issuance of Common Stock as payment for Services

During the quarter ended March 31, 2014, the Company reversed $21,000 of consulting compensation expense from a consulting agreement issued several years prior. The consultant never completed any of the tasks required under the contract and therefore did not meet the requirements to vest any of the 700,000 shares granted, but never issued, under the contract. The $21,000 was a reduction in selling, general & administrative expense.

XML

Notes Payable and Advances-related parties

3 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Notes Payable and Advances-related parties

Note 5. Notes Payable and Advances-related parties

Notes payable to unrelated parties consist of:

	March 31,		December 31,
	2014		2013
Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate 9% per annum, due December 20, 2001.		15		15
Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; due December 31, 2003; interest rate 8% per annum payable after December 31, 2003		21		21
	$	36	$	36

The Company has failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above. Such notes require the holder to notify the Company in writing of a declaration of default at which time a cure period, as specified in each individual note, would commence. The Company has not received any written declarations of default from holders of its remaining outstanding notes payable.

During the three months ended March 31, 2014, the Company was advanced $17,000 from a related party. These advances are non-interest bearing and are due on demand. However, using an 8% annual interest rate, the Company has recorded a non-cash interest expense totaling approximately $2,000 on the outstanding balance for the quarter.

XML

Notes Payable and Advances-related parties (Parenthetical) (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Promissory note, interest rate	8.00%
Robert Shaw [Member]
Debt Instrument [Line Items]
Promissory note	$ 25,000	$ 25,000
Promissory note, date of issue	Sep. 20, 2001	Sep. 20, 2001
Promissory note, interest rate	9.00%	9.00%
Promissory note, due date	Dec. 20, 2001	Dec. 20, 2001
Ventana Medical Systems, Inc [Member]
Debt Instrument [Line Items]
Promissory note	$ 62,946	$ 62,946
Promissory note, date of issue	Nov. 30, 2003	Nov. 30, 2003
Promissory note, interest rate	8.00%	8.00%
Promissory note, due date	Dec. 31, 2003	Dec. 31, 2003

XML

Fixed Assets (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Furniture and fixtures	$ 40	$ 40
Laboratory equipment	508	508
Computer and communications equipment	261	261
Design and tooling	1,204	1,204
Property, Plant and Equipment, Gross, Total	2,013	2,013
Less accumulated depreciation and amortization	(2,013)	(2,008)
Total	$ 0	$ 5	[1]

[1] Derived from audited information

XML

Fixed Assets (Tables)

3 Months Ended

Mar. 31, 2014

Property, Plant and Equipment [Abstract]

Property and equipment estimated useful lives

Fixed assets consist of the following:

	March 31,		December 31,
	2014		2013
Furniture and fixtures	$	40	$	40
Laboratory equipment		508		508
Computer and communications equipment		261		261
Design and tooling		1,204		1,204
		2,013		2,013
Less accumulated depreciation and amortization		(2,013)		(2,008)
Total	$	—	$	5

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 7. Commitments and Contingencies

Legal Proceedings

There are no pending legal proceedings against the Company. To the Company’s knowledge, there have been no cases initiated by or against the Company, nor any cases resolved, since the date of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 was filed with the SEC.

The Company has been a party to a number of other proceedings, informal demands, or debt for services brought by former unsecured creditors to collect past due amounts for services. The Company is attempting to settle these demands and unfilled claims. The Company does not consider any of these claims to be material.

During the quarter ended March 31, 2014, the Company recorded a settlement totaling $66,000 of trade debt. The settlement was recorded as a reduction of selling, general and administration expense.

Contingencies

The Company has not filed its franchise returns for 2013, 2012, 2011, 2010 and 2009 or paid its franchise tax for those years. The Company believes that it has made adequate provision for the liability including penalties and interest.

XML

Subsequent Events

3 Months Ended

Mar. 31, 2014

Subsequent Events [Abstract]

Subsequent Events

Note 8. Subsequent Events

On April 3, 2014, the Company acquired 100% of the issued and outstanding capital stock of Medite Enterprises, Inc. and its wholly owned subsidiaries (“Medite”)and issued in consideration 1,468,750,000 of the Company’s common stock to the shareholders of Medite. Also, the Company issued 69,723,439 shares of common stock as payment for approximately $1.6 million in accrued wages owed by the Company.

Concurrent with the closing of the acquisition of Medite, the Company had an initial closing of the a private placement of the Company’s common stock. Pursuant to the Securities Purchase Agreement the Company issued 95,587,500 shares of common stock to accredited investors at an aggregate gross purchase price of $1,529,400. In conjunction with the issuance of the common stock, the Company paid cash commissions of $46,298, or 7%, to a placement agent.

Subsequent to the closing, the Company raised additional gross proceeds of $100,000 under the Private Placement.

XML

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2014

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses include the following:

	March 31,		December 31,
	2014		2013
Accrued interest	$	31	$	30
Accrued franchise and other taxes		341		328
Accrued compensation		50		40
Other accrued expenses		57		139
Total	$	479	$	537

XML

Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Line Items]
Accrued interest	$ 31	$ 30
Accrued franchise and other taxes	341	328
Accrued compensation	50	40
Other accrued expenses	57	139
Total	$ 479	$ 537	[1]

[1] Derived from audited information

XML

Stockholders' Equity (Deficit) (Summary of Preferred Stock) (Detail)	Mar. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Preferred stock, shares issued	373,355	373,355
Preferred stock, shares outstanding	373,355	373,355
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	47,250	47,250
Preferred stock, shares outstanding	47,250	47,250
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	93,750	93,750
Preferred stock, shares outstanding	93,750	93,750
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	38,333	38,333
Preferred stock, shares outstanding	38,333	38,333
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	175,000	175,000
Preferred stock, shares outstanding	175,000	175,000
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	19,022	19,022
Preferred stock, shares outstanding	19,022	19,022

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (Selling, General and Administrative Expenses [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Selling, General and Administrative Expenses [Member]
Settlement of trade debt	$ 66,000	$ 193,000

XML

Accrued Expenses

3 Months Ended

Mar. 31, 2014

Payables and Accruals [Abstract]

Accrued expenses

Note 4. Accrued Expenses

Accrued expenses include the following:

	March 31,		December 31,
	2014		2013
Accrued interest	$	31	$	30
Accrued franchise and other taxes		341		328
Accrued compensation		50		40
Other accrued expenses		57		139
Total	$	479	$	537

XML

Stockholders' Equity (Deficit) (Summary of Preferred Stock) (Parenthetical) (Detail)	0 Months Ended	3 Months Ended	12 Months Ended
	Mar. 15, 2014	Mar. 31, 2014	Dec. 31, 2013
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, cumulative dividend rate		10.00%	10.00%
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, cumulative dividend rate		10.00%	10.00%
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, cumulative dividend rate	10.00%	10.00%	10.00%
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, cumulative dividend rate		10.00%	10.00%

XML

Fixed Assets - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 5,000	$ 29,000